Should an oral proton‑pump inhibitor be given to a 41‑year‑old woman with recent acalculous cholecystitis who now presents with severe right‑upper‑quadrant pain, vomiting, leukocytosis, markedly elevated bilirubin and transaminases, a dilated common bile duct, probable acute cholangitis, and is taking rivaroxaban?

Should You Give Oral PPI to This Patient?

No, do not give an oral PPI to this patient with probable acute cholangitis on rivaroxaban—the priority is urgent biliary drainage, hemodynamic stabilization, and broad-spectrum antibiotics, not gastroprotection.

Clinical Reasoning

This 41-year-old woman presents with severe (grade III) acute cholangitis based on the Tokyo Guidelines criteria: right upper quadrant pain, vomiting, leukocytosis, markedly elevated bilirubin and transaminases, and dilated common bile duct 1, 2. The severity classification is critical here—she requires:

Immediate Management Priorities

1. Urgent biliary drainage (endoscopic or percutaneous transhepatic) after hemodynamic stabilization 1
2. Broad-spectrum antibiotics
3. Organ support/circulatory management as needed for severe cholangitis 1
4. Rivaroxaban management - likely needs to be held given urgent intervention requirements 3

Why PPI Is Not Indicated Here

The evidence for PPI use relates to chronic anticoagulation scenarios, not acute biliary sepsis:

• The guideline recommendation for PPI prophylaxis applies specifically to patients on simultaneous antiplatelet AND anticoagulant therapy to reduce GI bleeding risk 4
• This patient is on rivaroxaban monotherapy (no mention of aspirin or other antiplatelet agents)
• The 2004 guideline addresses chronic NSAID users on warfarin, not acute surgical emergencies 5

Critical Considerations

Rivaroxaban absorption concerns: The FDA label explicitly states that rivaroxaban absorption is site-dependent and should not be administered distal to the stomach 3. In a patient with:

• Vomiting
• Probable need for NPO status before urgent ERCP/drainage
• Potential biliary obstruction affecting GI function

Oral medication administration (including both rivaroxaban and PPI) becomes problematic.

The real risk here is not GI bleeding—it's biliary sepsis and procedural bleeding. The rivaroxaban itself poses a hemorrhagic risk, as documented in case reports of hemorrhagic cholecystitis secondary to rivaroxaban use 6.

What Actually Needs to Happen

1. Hold rivaroxaban given urgent need for biliary drainage procedure 3
2. Consider parenteral anticoagulation if oral medication cannot be taken during surgical intervention 3
3. Proceed with urgent endoscopic biliary drainage once hemodynamically stable 1
4. Address the underlying biliary pathology after acute cholangitis resolves 1

Common Pitfall to Avoid

Do not delay definitive treatment (biliary drainage) to optimize gastroprotection. The mortality risk from untreated severe cholangitis far exceeds any theoretical GI bleeding risk from short-term anticoagulation interruption. The Tokyo Guidelines are clear: severe cholangitis requires urgent drainage after stabilization 1, 2.

Regarding PPI and Cholangitis Risk

Interestingly, recent research suggests PPI use may actually be associated with increased risk of acute cholangitis in patients with choledocholithiasis (OR 1.64 after age adjustment) 7. While this patient's cholangitis is already established, this finding argues against routine PPI use in biliary disease.

Bottom line: Focus on treating the life-threatening cholangitis, not on adding gastroprotection that isn't indicated and may complicate management.